We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
In the latest trading session, Johnson & Johnson (JNJ - Free Report) closed at $263.40, marking a -1.44% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.28% for the day. Meanwhile, the Dow experienced a drop of 1.09%, and the technology-dominated Nasdaq saw an increase of 0.2%.
Heading into today, shares of the world's biggest maker of health care products had gained 12.76% over the past month, outpacing the Medical sector's gain of 7.8% and the S&P 500's gain of 1.64%.
Market participants will be closely following the financial results of Johnson & Johnson in its upcoming release. The company plans to announce its earnings on July 15, 2026. On that day, Johnson & Johnson is projected to report earnings of $2.83 per share, which would represent year-over-year growth of 2.17%. In the meantime, our current consensus estimate forecasts the revenue to be $25.11 billion, indicating a 5.75% growth compared to the corresponding quarter of the prior year.
JNJ's full-year Zacks Consensus Estimates are calling for earnings of $11.57 per share and revenue of $100.81 billion. These results would represent year-over-year changes of +7.23% and +7.02%, respectively.
It is also important to note the recent changes to analyst estimates for Johnson & Johnson. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Johnson & Johnson presently features a Zacks Rank of #3 (Hold).
Looking at valuation, Johnson & Johnson is presently trading at a Forward P/E ratio of 23.1. This expresses a premium compared to the average Forward P/E of 16 of its industry.
Meanwhile, JNJ's PEG ratio is currently 2.62. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 2.7.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 198, putting it in the bottom 20% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors
In the latest trading session, Johnson & Johnson (JNJ - Free Report) closed at $263.40, marking a -1.44% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.28% for the day. Meanwhile, the Dow experienced a drop of 1.09%, and the technology-dominated Nasdaq saw an increase of 0.2%.
Heading into today, shares of the world's biggest maker of health care products had gained 12.76% over the past month, outpacing the Medical sector's gain of 7.8% and the S&P 500's gain of 1.64%.
Market participants will be closely following the financial results of Johnson & Johnson in its upcoming release. The company plans to announce its earnings on July 15, 2026. On that day, Johnson & Johnson is projected to report earnings of $2.83 per share, which would represent year-over-year growth of 2.17%. In the meantime, our current consensus estimate forecasts the revenue to be $25.11 billion, indicating a 5.75% growth compared to the corresponding quarter of the prior year.
JNJ's full-year Zacks Consensus Estimates are calling for earnings of $11.57 per share and revenue of $100.81 billion. These results would represent year-over-year changes of +7.23% and +7.02%, respectively.
It is also important to note the recent changes to analyst estimates for Johnson & Johnson. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Johnson & Johnson presently features a Zacks Rank of #3 (Hold).
Looking at valuation, Johnson & Johnson is presently trading at a Forward P/E ratio of 23.1. This expresses a premium compared to the average Forward P/E of 16 of its industry.
Meanwhile, JNJ's PEG ratio is currently 2.62. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 2.7.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 198, putting it in the bottom 20% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.